glp-1 obesity drug news today october 23 2025 oct GLP-1 Drugs: 2025 Pulse Survey (U.S.) The Multi-Sector Impacts of GLP-1RA
Description
2 and Additional file 1: Fig
Specifically, the ELIXA (lixisenatide) trial studied patients with T2DM who had recent acute coronary syndrome and found that the addition of lixisenatide to conventional therapy did not result in a significant difference in cardiovascular endpoints relative to placebo (Table 1) [56]
However, no statistically significant interaction of group by time was observed, indicating a lack of evidence that GLP-1RAs differentially modulate the increase in craving across the drinking session
1 T2DM remains as one of the leading causes of disability and death worldwide mainly due to its long-term vascular complications
The inhibitory effect of GLP-1R analogs on reward behaviors is blunted in mice with CNS-specific deletion of GLP-1R [748]
Patients regained weight by half roughly every 23 weeks, with broadly similar modeled trajectories across different GLP-1RAs
